RxDoctor Payments Data

Pallavi Heda, MD

Endocrinology, Diabetes & Metabolism · Tysons, VANPI 1124313754

Payments from drug & device makers

$2,176in general payments, 2019–2025

Across 48 payments — averaging $45.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$433
  • IBSA Pharma Inc.$337
  • Medtronic$190
  • AstraZeneca$163
  • Insulet Corporation$150
  • Dexcom, Inc.$145
  • plus $759 from 11 others

What the payments were for

  • Food & beverage$2,16099%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,176 in reported general payments places this provider in the 55th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

See all endocrinology, diabetes & metabolism providers in Virginia

Medicare billing

Part B allowed, 2024
$60,814
Medicare patients
173
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$104,842
JardianceEmpagliflozin66$92,927
TrulicityDulaglutide33$56,794
MounjaroTirzepatide30$36,820
FarxigaDapagliflozin Propanediol19$25,774
Synjardy XrEmpagliflozin/Metformin Hcl11$17,718
TradjentaLinagliptin14$14,353
Tresiba Flextouch U-100Insulin Degludec14$11,727
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,518
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,032
Novolog FlexpenInsulin Aspart15$3,879
Humalog Kwikpen U-100Insulin Lispro13$3,457
SynthroidLevothyroxine Sodium36$3,003
Nano 2nd Gen Pen NeedlePen Needle, Diabetic28$2,644
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$2,406

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$88$124,99891 claims
Novo NordiskOzempic$141$104,84244 claims
Lilly USA, LLCTrulicity, Mounjaro$433$93,61463 claims
AstraZenecaFarxiga$163$25,77419 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$21$10,51812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.

Other endocrinology, diabetes & metabolism in Tysons

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →